-
-
-
-
-
-
-
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)
-
-
-
-
-
-
-
NextCure Provides Business Update and Reports Second Quarter 2022 Financial Results
-
-
-
-
-
-
-
NextCure Inc. (NXTC) and Collaborators Report Data on Targets in Development
-
-
-
-
-
-
-
NextCure Announces Presentations on Targets in Development by Collaborators at American Society of Hematology Annual Meeting
-
-
-
-
-
-
-
Form S-1 NextCure, Inc.
-
-
-
66,407 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

